FDA Fast-Tracks Treatment for Fatal Genetic Brain Disease Alexander Disease Drug Receives Priority Review Status The FDA has granted Priority Review designation to zilganersen, a potential treatment for Alexander disease — a rare, fatal genetic disorder that affects the brain and nervous system. This designation expedites the review process for treatments